Biocardia Ebit vs Research Development Analysis

BCDA Stock

USD 2.28 0.09 3.80%

Biocardia financial indicator trend analysis is way more than just evaluating Biocardia prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biocardia is a good investment. Please check the relationship between Biocardia Ebit and its Research Development accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.

Ebit vs Research Development

Ebit vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biocardia Ebit account and Research Development. At this time, the significance of the direction appears to have pay attention.

The correlation between Biocardia's Ebit and Research Development is -0.97. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Research Development in the same time period over historical financial statements of Biocardia, assuming nothing else is changed. The correlation between historical values of Biocardia's Ebit and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Biocardia are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Ebit i.e., Biocardia's Ebit and Research Development go up and down completely randomly.

Correlation Coefficient

-0.97

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Ebit

Research Development

Most indicators from Biocardia's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biocardia current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.At present, Biocardia's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 12.57, whereas Selling General Administrative is forecasted to decline to about 3.3 M.

	2021	2022	2023	2024 (projected)
Interest Expense	9K	6K	6.9K	6.6K
Depreciation And Amortization	640K	82K	84K	79.8K

Interest Expense Depreciation And Amortization

Biocardia fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Term Investments	Current Deferred Revenue	Good Will	Inventory
Total Assets		0.02	-0.14	0.96	-0.15	-0.97	0.16	-0.24	0.99	-0.26	-0.61	0.99	0.3	0.54	-0.12	0.23	0.12	-0.06	-0.2	-0.37	0.99	0.54	0.65	0.07	0.51	-0.19
Other Current Liab	0.02		0.82	-0.24	0.9	0.19	-0.75	0.45	-0.11	0.84	0.4	-0.11	0.05	-0.64	-0.12	0.84	0.53	0.73	0.85	0.69	-0.08	-0.64	0.07	0.86	0.02	-0.7
Total Current Liabilities	-0.14	0.82		-0.42	0.75	0.34	-0.94	0.8	-0.27	0.78	0.48	-0.27	-0.08	-0.71	0.07	0.78	0.51	0.93	0.98	0.7	-0.23	-0.71	-0.2	0.87	-0.38	-0.89
Total Stockholder Equity	0.96	-0.24	-0.42		-0.39	-0.99	0.42	-0.44	0.99	-0.49	-0.71	0.99	0.32	0.7	-0.14	-0.02	-0.05	-0.33	-0.47	-0.57	0.98	0.69	0.64	-0.19	0.56	0.07
Property Plant And Equipment Net	-0.15	0.9	0.75	-0.39		0.36	-0.79	0.4	-0.27	0.96	0.57	-0.27	-0.19	-0.58	-0.12	0.7	0.43	0.76	0.85	0.89	-0.26	-0.57	-0.02	0.74	-0.18	-0.59
Net Debt	-0.97	0.19	0.34	-0.99	0.36		-0.35	0.35	-1.0	0.46	0.72	-1.0	-0.32	-0.66	0.09	-0.03	0.02	0.25	0.4	0.55	-0.99	-0.65	-0.65	0.12	-0.55	0.01
Retained Earnings	0.16	-0.75	-0.94	0.42	-0.79	-0.35		-0.78	0.27	-0.83	-0.58	0.27	0.22	0.6	0.0	-0.68	-0.41	-0.99	-0.95	-0.8	0.25	0.59	0.2	-0.81	0.51	0.89
Accounts Payable	-0.24	0.45	0.8	-0.44	0.4	0.35	-0.78		-0.32	0.45	0.29	-0.32	-0.31	-0.56	0.35	0.39	0.3	0.76	0.75	0.43	-0.29	-0.56	-0.19	0.63	-0.39	-0.71
Cash	0.99	-0.11	-0.27	0.99	-0.27	-1.0	0.27	-0.32		-0.38	-0.67	1.0	0.31	0.62	-0.11	0.11	0.02	-0.18	-0.33	-0.47	1.0	0.62	0.65	-0.05	0.53	-0.08
Non Current Assets Total	-0.26	0.84	0.78	-0.49	0.96	0.46	-0.83	0.45	-0.38		0.73	-0.38	-0.24	-0.61	-0.17	0.67	0.43	0.81	0.88	0.97	-0.37	-0.61	-0.25	0.73	-0.41	-0.6
Non Currrent Assets Other	-0.61	0.4	0.48	-0.71	0.57	0.72	-0.58	0.29	-0.67	0.73		-0.67	-0.27	-0.53	-0.47	0.25	0.1	0.54	0.55	0.8	-0.67	-0.52	-0.78	0.36	-0.74	-0.27
Cash And Short Term Investments	0.99	-0.11	-0.27	0.99	-0.27	-1.0	0.27	-0.32	1.0	-0.38	-0.67		0.31	0.62	-0.11	0.11	0.02	-0.18	-0.33	-0.47	1.0	0.62	0.65	-0.05	0.53	-0.08
Net Receivables	0.3	0.05	-0.08	0.32	-0.19	-0.32	0.22	-0.31	0.31	-0.24	-0.27	0.31		-0.11	-0.28	0.38	-0.37	-0.2	-0.18	-0.41	0.32	-0.12	0.12	0.12	0.33	-0.12
Common Stock Total Equity	0.54	-0.64	-0.71	0.7	-0.58	-0.66	0.6	-0.56	0.62	-0.61	-0.53	0.62	-0.11		-0.13	-0.56	-0.22	-0.53	-0.7	-0.54	0.6	1.0	0.35	-0.73	0.28	0.46
Common Stock Shares Outstanding	-0.12	-0.12	0.07	-0.14	-0.12	0.09	0.0	0.35	-0.11	-0.17	-0.47	-0.11	-0.28	-0.13		-0.2	0.18	-0.03	0.07	-0.15	-0.1	-0.13	0.36	0.0	0.18	0.03
Non Current Liabilities Total	0.23	0.84	0.78	-0.02	0.7	-0.03	-0.68	0.39	0.11	0.67	0.25	0.11	0.38	-0.56	-0.2		0.37	0.69	0.76	0.48	0.14	-0.56	0.05	0.82	-0.06	-0.82
Other Current Assets	0.12	0.53	0.51	-0.05	0.43	0.02	-0.41	0.3	0.02	0.43	0.1	0.02	-0.37	-0.22	0.18	0.37		0.42	0.53	0.41	0.06	-0.22	0.1	0.48	-0.04	-0.36
Other Stockholder Equity	-0.06	0.73	0.93	-0.33	0.76	0.25	-0.99	0.76	-0.18	0.81	0.54	-0.18	-0.2	-0.53	-0.03	0.69	0.42		0.93	0.77	-0.16	-0.53	-0.18	0.81	-0.51	-0.91
Total Liab	-0.2	0.85	0.98	-0.47	0.85	0.4	-0.95	0.75	-0.33	0.88	0.55	-0.33	-0.18	-0.7	0.07	0.76	0.53	0.93		0.81	-0.3	-0.7	-0.21	0.85	-0.4	-0.83
Property Plant And Equipment Gross	-0.37	0.69	0.7	-0.57	0.89	0.55	-0.8	0.43	-0.47	0.97	0.8	-0.47	-0.41	-0.54	-0.15	0.48	0.41	0.77	0.81		-0.47	-0.53	-0.35	0.61	-0.55	-0.49
Total Current Assets	0.99	-0.08	-0.23	0.98	-0.26	-0.99	0.25	-0.29	1.0	-0.37	-0.67	1.0	0.32	0.6	-0.1	0.14	0.06	-0.16	-0.3	-0.47		0.59	0.65	-0.02	0.53	-0.11
Common Stock	0.54	-0.64	-0.71	0.69	-0.57	-0.65	0.59	-0.56	0.62	-0.61	-0.52	0.62	-0.12	1.0	-0.13	-0.56	-0.22	-0.53	-0.7	-0.53	0.59		0.34	-0.73	0.27	0.46
Short Term Investments	0.65	0.07	-0.2	0.64	-0.02	-0.65	0.2	-0.19	0.65	-0.25	-0.78	0.65	0.12	0.35	0.36	0.05	0.1	-0.18	-0.21	-0.35	0.65	0.34		0.0	0.8	0.02
Current Deferred Revenue	0.07	0.86	0.87	-0.19	0.74	0.12	-0.81	0.63	-0.05	0.73	0.36	-0.05	0.12	-0.73	0.0	0.82	0.48	0.81	0.85	0.61	-0.02	-0.73	0.0		-0.13	-0.81
Good Will	0.51	0.02	-0.38	0.56	-0.18	-0.55	0.51	-0.39	0.53	-0.41	-0.74	0.53	0.33	0.28	0.18	-0.06	-0.04	-0.51	-0.4	-0.55	0.53	0.27	0.8	-0.13		0.32
Inventory	-0.19	-0.7	-0.89	0.07	-0.59	0.01	0.89	-0.71	-0.08	-0.6	-0.27	-0.08	-0.12	0.46	0.03	-0.82	-0.36	-0.91	-0.83	-0.49	-0.11	0.46	0.02	-0.81	0.32

Click cells to compare fundamentals

Biocardia Account Relationship Matchups

Biocardia fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	7.7M	23.4M	15.7M	9.8M	3.0M	2.8M
Other Current Liab	1.8M	2.2M	2.9M	3.0M	1.3M	806.1K
Total Current Liabilities	4.0M	4.2M	3.7M	3.6M	3.6M	3.8M
Total Stockholder Equity	2.4M	19.2M	10.4M	4.9M	(1.6M)	(1.5M)
Property Plant And Equipment Net	1.2M	712K	2.1M	1.9M	1.4M	744.1K
Net Debt	(4.4M)	(20.8M)	(11.0M)	(5.7M)	212K	222.6K
Retained Earnings	(101.1M)	(116.1M)	(128.7M)	(140.6M)	(152.2M)	(144.6M)
Accounts Payable	914K	746K	507K	683K	890K	934.5K
Cash	5.6M	21.4M	12.9M	7.4M	1.1M	1.0M
Non Current Assets Total	1.3M	766K	2.2M	1.9M	1.5M	1.6M
Cash And Short Term Investments	5.6M	21.4M	12.9M	7.4M	1.1M	1.0M
Net Receivables	274K	147K	850K	201K	63K	59.9K
Common Stock Total Equity	38K	43K	7K	16K	18.4K	17.5K
Common Stock Shares Outstanding	5.6M	674.6K	1.1M	1.2M	1.4M	1.4M
Liabilities And Stockholders Equity	7.7M	23.4M	15.7M	9.8M	3.0M	2.8M
Non Current Liabilities Total	1.3M	2.7M	1.6M	1.3M	982K	630.9K
Other Current Assets	642K	401K	924K	300K	295K	436.7K
Other Stockholder Equity	103.4M	135.2M	139.1M	145.5M	150.5M	158.1M
Total Liab	5.3M	4.2M	5.3M	4.9M	4.6M	4.8M
Total Current Assets	6.4M	22.7M	13.5M	7.9M	1.5M	1.4M
Common Stock	7K	16K	17K	20K	24K	22.8K
Current Deferred Revenue	732K	1.4M	1.5M	965K	759K	750.8K
Inventory	4K	(850K)	1.0	(201K)	(180.9K)	(171.9K)
Net Tangible Assets	2.4M	19.2M	10.4M	4.9M	5.6M	5.5M
Retained Earnings Total Equity	(72.5M)	(86.4M)	(101.1M)	(116.1M)	(104.5M)	(99.2M)
Capital Surpluse	83.5M	90.1M	103.4M	135.2M	155.5M	163.3M
Property Plant Equipment	1.2M	712K	2.1M	1.8M	2.0M	2.1M
Net Invested Capital	2.4M	19.2M	10.4M	4.9M	(1.6M)	(1.5M)
Net Working Capital	2.4M	18.4M	9.8M	4.3M	(2.1M)	(2.0M)
Capital Stock	7K	16K	17K	20K	24K	16.9K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Biocardia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biocardia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocardia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocardia Stock:

How To Invest In Biocardia

Details

Is Biocardia Stock a good investment?

Details

What is Biocardia's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.

You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.03)

Revenue Per Share

0.264

Quarterly Revenue Growth

(0.93)

Return On Assets

(1.16)

Return On Equity

(7.04)

The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biocardia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biocardia Ebit vs Research Development Analysis

Ebit vs Research Development

Ebit vs Research Development Correlation Analysis

Correlation Coefficient

Ebit

Research Development

Biocardia fundamental ratios Correlations

Biocardia Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biocardia fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Cash	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.99	Retained Earnings
Total Current Assets	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Debt	- 0.97	Total Assets